Lowell L. Hart - Concepedia

Author

Lowell L. Hart

Florida Cancer Specialists & Research Institute

Also Known As

L L Hart, L. L. Hart, L.L. Hart, Lowell Hart, Lowell L Hart, Lowell L. Hart

206

Publications

10.2K

Citations

H-Index

Concepts

All Affiliations

Florida Cancer Specialists & Research Institute Sarah Cannon Tennessee Oncology The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center

About

Lowell L. Hart is an author at Florida Cancer Specialists & Research Institute specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	37	2.7K
2	Health Sciences	11	12	586
3	Cell Biology	3	3	44
4	Applied Physiology	1	1	17
5	Athletic Training	1	1	17

Lowell L. Hart

Publications

9.3K

Citations

H-Index

Page 1

	Year	Citations
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, New England Journal of Medicine	2016	1.9K
Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial Mace L. Rothenberg, Amit M. Oza, Robert Bigelow, Journal of Clinical Oncology	2003	642
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study Howard S. Höchster, Lowell L. Hart, Ramesh K. Ramanathan, Journal of Clinical Oncology	2008	620
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, The Lancet Oncology Pharmacological StudyEfficacy DataPharmacologyClinical TrialsPharmacotherapy	2012	554
Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer Roy S. Herbst, Vincent O’Neill, Louis Fehrenbacher, Journal of Clinical Oncology	2007	396
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial Roy S. Herbst, Rafat Ansari, F. Bustin, The Lancet OncologyErlotinib Versus ErlotinibMedicineMetronomic TherapyBronchial Neoplasm	2011	391
Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer Shirin Khambata‐Ford, Christopher Harbison, Lowell L. Hart, Journal of Clinical Oncology Patient SelectionImmunologyPathologyPotential Predictive MarkersTumor Biology	2010	268
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors Daniel D. Von Hoff, Monica Mita, Ramesh K. Ramanathan, Clinical Cancer Research	2016	262
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer Karen A. Autio, Robert Dreicer, Justine Anderson, JAMA Oncology	2018	241
A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer Jordan Berlin, Johanna C. Bendell, Lowell L. Hart, Clinical Cancer Research	2012	173

Page 1